Bioverativ alleges patent infringement by CSL

Australian plasma products giant CSL Limited (ASX: CSL) says it has become aware that Bioverativ (Nasdaq: BIVV) has filed complaints in the US District Court for the District of Delaware and with the International Trade Commission.

Bioverativ, the hemophilia business spun out of US biotech major Biogen (Nasdaq: BIIB) earlier this year, alleges that the use of Idelvion, a novel factor IX albumin fusion protein developed by CSL Behring, by patients and physicians constitutes patent infringement, and that by virtue of the US Food and Drug Administration approved label for Idelvion, CSL therefore infringes three Bioverativ patents. Bioverativ says Idelvion is similar to its Alprolix (coagulation Factor IX [recombinant]).

CSL is highly confident of its intellectual property position for Idelvion, a product of over a decade of innovative research by CSL Behring and representative of a major advance for patients suffering hemophilia B, and will vigorously defend against the claim.